Target Name: OGFR-AS1
NCBI ID: G101409261
Other Name(s): OGFR antisense RNA 1

OGFR-AS1: A Potential Drug Target and Biomarker

The OGFR gene is a key regulator of angiogenesis, which is the process by which the blood vessels grow and develop in the body. One of the proteins encoded by the OGFR gene is OGFR-AS1, which has been shown to play a crucial role in the regulation of angiogenesis and the development of cancer. In this article, we will discuss OGFR-AS1 as a potential drug target and biomarker, and its potential clinical applications.

OGFR-AS1: Structure and Function

OGFR-AS1 is a 21-kDa transmembrane protein that consists of an extracellular region, a transmembrane region, and an intracellular region. The extracellular region contains a N-terminus that is involved in the formation of the extracellular matrix, while the transmembrane region contains a series of hydrophobic domains that are involved in the stability of the membrane. The intracellular region contains a series of tyrosine residues that are involved in the regulation of cell signaling pathways.

One of the most significant functions of OGFR-AS1 is its role in the regulation of angiogenesis. Angiogenesis is the process by which new blood vessels grow and develop in the body, and it is a critical process for the development and maintenance of tissues. OGFR-AS1 has been shown to play a crucial role in the regulation of angiogenesis by controlling the expression of genes involved in blood vessel growth and development.

In addition to its role in angiogenesis, OGFR-AS1 has also been shown to play a critical role in the regulation of cancer cell growth and survival. For example, OGFR-AS1 has been shown to inhibit the growth and survival of cancer cells by preventing the formation of blood vessels that supply the cells with oxygen and nutrients. This is why OGFR-AS1 has been identified as a potential drug target for cancer treatment.

OGFR-AS1 as a Drug Target

The development of new cancer treatments is a major focus of research in the field of cancer treatment. One of the challenges in the development of new cancer treatments is the development of resistance to these treatments, which can limit their effectiveness and increase the risk of side effects. OGFR-AS1 has been shown to be a potential drug target for cancer treatment by its ability to inhibit the growth and survival of cancer cells.

One of the potential strategies for targeting OGFR-AS1 is the use of small molecules, such as inhibitors, that can bind to the protein and prevent it from functioning. These inhibitors can be administered to cancer cells to inhibit the growth and survival of the cells, leading to a reduction in the number of cancer cells.

In addition to small molecules, OGFR-AS1 has also been shown to be a potential drug target for cancer treatment by its ability to stimulate the production of antibodies that can recognize and destroy cancer cells. This is an attractive approach to cancer treatment because it does not involve the use of toxic drugs and has the potential to be effective for a long time.

OGFR-AS1 as a Biomarker

In addition to its role in the regulation of angiogenesis and cancer cell growth, OGFR-AS1 has also been shown to be a potential biomarker for the diagnosis and prognosis of cancer. This is because its expression has been shown to be affected by a variety of factors, including cancer status, tissue type, and the presence of certain genetic alterations.

For example, OGFR-AS1 has been shown to be downregulated in the majority of human cancers, which suggests that it may be a useful biomarker for the diagnosis and prognosis of cancer. In addition, OGFR-AS1 has been shown to be involved in the regulation of angiogenesis, which is a critical process for the development and maintenance of tissues. This suggests that OGFR-AS1 may be a useful biomarker for the diagnosis and prognosis of

Protein Name: OGFR Antisense RNA 1

More Common Targets

OGFRL1 | OGFRP1 | OGG1 | OGN | OGT | OIP5 | OIP5-AS1 | OIT3 | OLA1 | OLA1P1 | OLAH | OLFM1 | OLFM2 | OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1